Last updated 9 days ago
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
303 patients around the world
Available in Brazil, Argentina, Mexico, United States
Amgen
10Research sites
303Patients around the world
This study is for people with
Solid tumors
Breast Cancer
Cervical cancer
Head and neck cancer
Lung cancer
Ovarian cancer
Requirements for the patient
To 99 Years
All Gender
Medical requirements
Sites
Sociedad de Beneficencia Hospital Italiano - Córdoba
Recruiting
Sociedad de Beneficencia Hospital Italiano - Córdoba
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Hospital Italiano de La Plata
Recruiting
Hospital Italiano de La Plata
Recruiting
Fundación Médica de Río Negro y Neuquén - Cipolletti
Recruiting
Fundación Médica de Río Negro y Neuquén - Cipolletti
Recruiting
Centro Oncológico Korben
Recruiting
Centro Oncológico Korben
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Hospital Alemán
Recruiting
Hospital Alemán
Recruiting
Hospital Universitario de Saltillo
Recruiting
Hospital Universitario de Saltillo
Recruiting
Hospital Universitario Virgen de la Victoria
Recruiting
Hospital Universitario Virgen de la Victoria
Recruiting
Hospital Clínico Universitario de Santiago - CHUS
Recruiting
Hospital Clínico Universitario de Santiago - CHUS
Recruiting
StudyFORTITUDE-301
SponsorAmgen
Study typeInterventional
Conditions
Solid tumorsBreast CancerCervical cancerHead and neck cancerLung cancer
Requirements
To 99 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05325866
